.Pharmacolibrary.Drugs.ATC.L.L01XK52 .Pharmacolibrary.Drugs.ATC.L.L01XK52| name: | NiraparibAndAbiraterone | |
| ATC code: | L01XK52 | route: | orally |
| compartments: | 1 | |
| dosage: | 200 | mg |
| volume of distribution: | 1070 | L |
| clearance: | 17 | L/h |
| other parameters in model implementation | ||
This is a fixed-dose combination medication containing niraparib, a PARP inhibitor used primarily in ovarian cancer, and abiraterone acetate, a selective CYP17 inhibitor used in the treatment of metastatic castration-resistant prostate cancer. The combination is intended for treatment of adult patients with certain types of prostate cancer and was approved by the European Union in May 2023.
No published literature with population or compartmental pharmacokinetic models for the fixed-dose combination of niraparib and abiraterone (L01XK52) is currently available as of June 2024. Parameter estimates were inferred based on the pharmacokinetic characteristics of individual components and regulatory approval documentation.